
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Examples of the various video formats that can now be offered from Advanstar Pharma Science Multimedia
Regular Video Series
Slideshows
Event Wrap Up
News Features
Special Projects
Live Tradeshow Coverage
eBook Videos






